Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Supine Versus Prone Whole-Breast Radiotherapy in Thai Women After Breast-Conserving Surgery (SPAR-Breast)

10. november 2026 opdateret af: Mahidol University

Dosimetric Comparison of Supine Versus Prone Whole-Breast Radiotherapy in Thai Women After Breast-Conserving Surgery: A Prospective Paired Study

This study aims to compare two positions used for whole-breast radiation therapy in Thai women who have undergone breast-conserving surgery: lying on the back (supine) and lying face down (prone).

Radiation therapy after breast-conserving surgery helps reduce the risk of breast cancer returning. However, some radiation may reach nearby organs, particularly the heart and lungs. The position used during treatment may affect how much radiation these organs receive.

In this study, 24 women will undergo radiation treatment planning CT scans in both the supine and prone positions. Researchers will create a radiation treatment plan for each position and compare how well the plans cover the breast while minimizing radiation exposure to the heart and lungs. Each participant will receive actual radiation treatment in only one of the two positions, selected based on treatment planning results and clinical suitability.

The study will also assess patient comfort, positioning accuracy, treatment setup time, and treatment-related side effects.

The findings may help identify which patients are more likely to benefit from prone positioning and support individualized breast radiation treatment planning in Thai women.

Studieoversigt

Status

Ikke rekrutterer endnu

Detaljeret beskrivelse

This is a prospective paired within-patient dosimetric study comparing supine and prone whole-breast radiotherapy in Thai women after breast-conserving surgery.

Each participant will undergo CT simulation in both the supine and prone positions. A three-dimensional conformal radiotherapy plan will be generated for each position using the same planning approach. The two plans will first be evaluated for acceptable target coverage. They will then be compared according to radiation exposure to organs at risk, with primary consideration given to the heart and ipsilateral lung and secondary consideration given to the contralateral lung and contralateral breast.

The treatment position used for actual radiotherapy will be selected using a predefined plan-comparison algorithm based on target coverage and organ-at-risk dose criteria. If both plans are otherwise comparable, patient preference may be used as a final decision factor. The participant will receive treatment in only one selected position.

The study will also explore whether anatomical characteristics, including chest wall and breast-related measurements, are associated with greater dosimetric benefit from prone positioning. Additional assessments include treatment setup time, positioning accuracy, patient comfort and preference, and treatment-related toxicity.

The study is intended to provide institution-specific data on individualized selection of breast radiotherapy position in Thai women rather than assuming that either supine or prone positioning is preferable for all patients.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

24

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Inclusion Criteria:

  • Histologically confirmed breast carcinoma or ductal carcinoma in situ (DCIS)
  • Status post breast-conserving surgery
  • Planned adjuvant breast-only radiotherapy
  • No indication for regional nodal irradiation
  • Preoperative breast size corresponding to bra cup A-B, defined by the patient's preoperative bra size or a bust-minus-underbust circumference difference of <14 cm
  • Age ≥18 years

Exclusion Criteria:

  • Planned treatment using Deep Inspiration Breath Hold (DIBH)
  • Bilateral breast cancer
  • Previous radiotherapy to the ipsilateral breast
  • Unable to tolerate either the prone or supine position
  • Breast volume >750 cm³
  • Pre-existing heart disease or lung disease
  • Active connective tissue disease
  • Pregnant or found to be pregnant

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Supine and Prone Whole-Breast Radiotherapy Planning

All participants will undergo CT simulation and treatment planning in both the supine and prone positions. The two plans will be compared for target coverage and radiation dose to organs at risk, including the heart and ipsilateral lung. Actual whole-breast radiotherapy will be delivered in only one selected position based on predefined plan-selection criteria and clinical suitability.

Participants will undergo CT simulation in both supine and prone positions after breast-conserving surgery. Whole-breast radiotherapy plans will be generated for both positions using 3-dimensional conformal radiotherapy (3D-CRT). Target coverage and organ-at-risk dosimetric parameters will be compared between the two plans. The treatment position will be selected according to predefined target coverage and organ-at-risk criteria. Participants will receive actual radiotherapy in the selected position only. The prescribed whole-breast dose is 40 Gy in 15 fractions, with a simultaneous integrated boost to 48 Gy in selected patients.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Mean Heart Dose in Supine Versus Prone Treatment Plans
Tidsramme: within 4 weeks after both CT simulations

Mean radiation dose to the heart, measured in Gray (Gy), will be obtained from the dose-volume histogram for both the supine and prone treatment plans within the same participant. The mean heart dose will be compared between the two positions while maintaining acceptable target coverage.

within 4 weeks after both CT simulations
Mean Ipsilateral Lung Dose in Supine Versus Prone Treatment Plans
Tidsramme: within 4 weeks after both CT simulations

Radiation dose to the lung on the same side as the treated breast will be assessed from the dose-volume histogram for both supine and prone treatment plans. Dosimetric parameters will include mean ipsilateral lung dose, and will be compared within the same participant while maintaining acceptable target coverage.

within 4 weeks after both CT simulations

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
PTV_Eval V95 in Supine Versus Prone Treatment Plans
Tidsramme: within 4 weeks after both CT simulations

PTV_Eval V95, defined as the percentage of PTV_Eval receiving at least 95% of the prescribed dose, will be obtained from the dose-volume histogram for both the supine and prone treatment plans within the same participant. PTV_Eval V95 will be compared between the two positions. The unit of measure is percentage (%).

within 4 weeks after both CT simulations
Treatment time from initial setup to treatment completion
Tidsramme: within 4 weeks after treatment completion

Time required for patient positioning and setup until treatment is completed will be recorded and compared between the supine and prone positions. Time will be reported in minutes.

within 4 weeks after treatment completion
translational X Positioning Accuracy
Tidsramme: within 4 weeks after treatment completion

Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational X axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm).

within 4 weeks after treatment completion
translational Y Positioning Accuracy
Tidsramme: within 4 weeks after treatment completion

Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational Y axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm).

within 4 weeks after treatment completion
translational Z Positioning Accuracy
Tidsramme: within 4 weeks after treatment completion

Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational Z axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm).

within 4 weeks after treatment completion
Patient Satisfaction Score
Tidsramme: within 1 hours after both CT simulations, and within 1 hours after treatment completion

Patient satisfaction will be assessed using a study-specific questionnaire. Comfort and satisfaction will be rated using a 5-point Likert scale ranging from 1 to 5, with higher scores indicating greater comfort and satisfaction with the position.

within 1 hours after both CT simulations, and within 1 hours after treatment completion
Radiation Therapist Satisfaction
Tidsramme: within 1 hours after treatment completion

Radiation therapist satisfaction with patient positioning will be assessed using a study-specific 5-point Likert satisfaction scale for the supine and prone positions. Scores range from 1 to 5, with higher scores indicating greater radiation therapist satisfaction with the positioning technique.

within 1 hours after treatment completion
Acute Skin Toxicity using CTCAE Version 5.0 graing scale
Tidsramme: Weekly during radiotherapy for about 3 weeks and at 1 month after treatment completion

Acute radiation-related skin toxicity will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. Radiation dermatitis will be graded from Grade 0 to Grade 5, with higher grades indicating greater severity of skin toxicity.

Weekly during radiotherapy for about 3 weeks and at 1 month after treatment completion

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Tanun Jitwatcharakomol, MD, Mahidol University

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. december 2026

Primær færdiggørelse (Anslået)

31. december 2027

Studieafslutning (Anslået)

31. december 2028

Datoer for studieregistrering

Først indsendt

28. oktober 2026

Først indsendt, der opfyldte QC-kriterier

10. november 2026

Først opslået (Faktiske)

16. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner